AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study shows strong treatment for ovarian cancer.
2003 JUL 3 - (NewsRx.com & NewsRx.net) -- AltaRex Corp. (TSX: AXO, OTC: ALXFF) announced the results of a phase II trial of OvaRex (oregovamab) at the annual meeting of the American Society of Clinical Oncologists (ASCO).
The results of this placebo-controlled trial in stage III/IV ovarian cancer patients identified a population that exhibited a strongly favorable outcome. In this group of patients, median time to disease relapse for OvaRex treated patients (n=3D34) was 24 months, versus 10.8 months for placebo (n=3D33) treated patients (p=3D0.06).
The study was a randomized Phase II multi-center trial assessing the ability of OvaRex to influence time to progression for advanced ovarian cancer patients with no evidence of disease and normalized CA125 following front-line surgery and chemotherapy. Currently there is no approved therapy for patients in this treatment period. The study population was typical of this cancer population, and the treatment arms were well balanced. One hundred forty-five patients were randomized into the study. The clinical outcome favored OvaRex treatment, 13.3 versus 10.3 months in ...
- Plan to boost number of clinical oncologists.(Brief Article)
- Newspaper article from: New Straits Times June 10, 2001 700+ words
...KUALA LUMPUR, Thurs. - The country is short of clinical oncologists, and doctors will be trained locally and abroad...Universiti Hospital and Universiti Sains Malaysia. Clinical oncologists are specialists in radiotherapy and chemotherapy...
- Public Interest Watch Calls for Government Investigation of Ketchum...
- Press release article from: PR Newswire September 9, 2004 700+ words
...simultaneously is under contract with the American Society of Clinical Oncologists (ASCO) to scuttle some of the very changes HHS is paying...Fein also noted, "We believe the American Society of Clinical Oncologists is just as at fault as Ketchum. ASCO's decision to...
- American Society of Clinical Oncologists.(NEWS IN A MINUTE)(Brief Article)
- Magazine article from: The Food Institute Report May 23, 2005 700+ words
...treatment had a 24% lower rate of new cancers compared with those on a healthful, but higher-fat diet, according to research made public at the annual meeting of the AMERICAN SOCIETY OF CLINICAL ONCOLOGISTS ... Star Tribune (May 17)
- QUADRAMET(TM) PHASE III CLINICAL TRIAL RESULTS PRESENTED AT AMERICAN SOCIETY OF...
- Press release article from: PR Newswire May 20, 1996 700+ words
...cancer that has spread to bone, will be the subject of a poster presentation at the 1996 American Society of Clinical Oncologists Annual Meeting (ASCO). CYTOGEN has licensed Quadramet in the United States to The DuPont Merck Pharmaceutical...
- ZADAXIN Significantly Increases Survival in Melanoma Animal Study; Study...
- Press release article from: Business Wire November 11, 2002 700+ words
...results were presented on Saturday, Nov. 9, at the Molecular Therapeutics Symposium of the American Society of Clinical Oncologists (ASCO) in San Diego. Mice inoculated with melanoma tumor were randomized into three treatment and one control...
- Older oncologist more likely to stress prevention. (survey of members of the...
- Newspaper article from: Cancer Weekly February 3, 1992 700+ words
California A nationwide survey of 729 members of the American Society of Clinical Oncologists (ASCO) found a significantly more favorable attitude toward cancer prevention and control efforts among physicians with more...
- OvaRex(R) Study Demonstrates Clinical Benefit for Ovarian Cancer Patients.
- Press release article from: PR Newswire June 2, 2003 700+ words
...the American Society of Clinical Oncologists (ASCO) in Chicago. The...trial in stage III/IV ovarian cancer patients identified a population...progression for advanced ovarian cancer patients with no evidence...for women with advanced ovarian cancer," said Dr. Jonathan...
- OvaRex(R) Study Demonstrates Clinical Benefit for Ovarian Cancer Patients;...
- Press release article from: PR Newswire June 2, 2003 700+ words
...the American Society of Clinical Oncologists (ASCO) in Chicago. The...trial in stage III/IV ovarian cancer patients identified a population...progression for advanced ovarian cancer patients with no evidence...for women with advanced ovarian cancer," said Dr. Jonathan...
- OvaRex study demonstrates clinical benefit for ovarian cancer patients.
- News wire article from: Asia Africa Intelligence Wire June 2, 2003 700+ words
...the American Society of Clinical Oncologists (ASCO) in Chicago. The...trial in stage III/IV ovarian cancer patients identified a population...progression for advanced ovarian cancer patients with no evidence...stage III/IV advanced ovarian cancer following successful ...
- AVAX Technologies Awarded Orphan Drug Status for Its O-Vax(TM) Ovarian Cancer...
- Press release article from: PR Newswire September 27, 2000 700+ words
...The company's ovarian cancer program follows two...studies of advanced ovarian cancer patients, which...patients with advanced ovarian cancer. As reported in...American Association of Clinical Oncologists meeting, data on...
Source: HighBeam Research, Study shows strong treatment for ovarian cancer.